Next Generation Drug Conjugates Market to Soar with Over 20% CAGR: Revolutionizing Rare Disease Treatment and Oncology Therapies - ResearchAndMarkets.com
Retrieved on:
火曜日, 10月 17, 2023
Pharmaceutical, Health, Oncology, Ligand, Cancer, Lipid, Antibody, USFDA, U.S.–Afghanistan Strategic Partnership Agreement, Lutetium (177Lu) oxodotreotide, LICA, Oligonucleotide, Traction, Success, Radionuclide, USD, Therapy, Janssen, Generic drug, Novartis, SMDC, FDA, AstraZeneca, Peptide, Growth, Brown sugar, Rare disease, Region, Rare, Clinical trial, PRRT, Spacecraft, N-Acetylgalactosamine, Alnylam Pharmaceuticals, Patient, Fine chemical, Pharmaceutical industry, Vaccine, Lutetium (177Lu) vipivotide tetraxetan
This growing burden of rare diseases has driven the search for alternative therapies, and next generation drug conjugates have emerged as a viable option.
Key Points:
- This growing burden of rare diseases has driven the search for alternative therapies, and next generation drug conjugates have emerged as a viable option.
- Advantages Over Antibody Drug Conjugates (ADCs): Next generation drug conjugates share similarities with antibody drug conjugates (ADCs) but offer advantages in terms of clinical efficacy and stability.
- Types of Next Generation Drug Conjugates: Various types of next generation drug conjugates have emerged, including peptide drug conjugates, peptide receptor radionuclide therapy (peptide radionuclide conjugates), GalNac conjugates, peptide oligonucleotide conjugates, si-RNA conjugates, small molecule-drug conjugates (SMDC), ligand-conjugated antisense medicine (LICA), and peptide-conjugated phosphorodiamidate morpholino oligomers (PPMO).
- Peptide Drug Conjugates: Peptide drug conjugates have emerged as a promising alternative to antibody drug conjugates (ADCs).